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RESEARCH ARTICLE Open Access
A pragmatic lifestyle modification
programme reduces the incidence of
predictors of cardio-metabolic disease and
dysglycaemia in a young healthy urban
South Asian population: a randomised
controlled trial
Mahen Wijesuriya1, Nikolaos Fountoulakis2, Nicola Guess3, Sarath Banneheka1, Laksha Vasantharajah1,
Martin Gulliford4, Giancarlo Viberti2, Luigi Gnudi2 and Janaka Karalliedde2*
Abstract
Background: There is an increasing incidence of type 2 diabetes mellitus (T2DM) in young urban South-Asians. We
tested the effect of a pragmatic trimonthly lifestyle modification (LSM) programme (P-LSM) versus a less-intensive
12-monthly control LSM (C-LSM) intervention on a primary composite endpoint of predictors of cardio-metabolic
disease (new onset T2DM, hypertension, impaired glucose tolerance (IGT), impaired fasting glycaemia (IFG) and markers
of cardio-renal disease) in participants aged 5–40 years with risk factors for T2DM.
Methods: This was a randomised controlled trial performed at the National Diabetes Centre, Sri-Lanka. We individually
randomised 4672 participants at risk of T2DM, of whom 3539 (mean age 22.5 (range 6–40 years, 48% males) received
either trimonthly (P-LSM n = 1726) or 12-monthly (C-LSM n = 1813) peer educator advice aimed at reducing weight,
improving diet, reducing psychological stress and increasing physical activity.
Results: During a median follow-up of 3 years, the cumulative incidence of the primary endpoint was n = 479 in P-LSM
(74 per 1000 person years) vs. 561 in C-LSM (96 per 1000 person years), with an incident rate ratio (IRR) of 0.89
(95% CI 0.83–0.96, P = 0.02). In post hoc analyses, new onset dysglycaemia (T2DM, IFG and IGT), was the major
contributor to the composite and was significantly reduced by P-LSM (IRR 0.9, 95% CI 0.83–0.97, P = 0.01). A
significant impact of P-LSM on the incidence of the composite endpoint was noted in 1725 participants (P-LSM
n = 850, C-LSM n = 875) aged below 18; P-LSM n = 140 (48 per 1000 person years) versus C-LSM n = 174 (55.4 per
1000 person years), with an IRR of 0.83 (95% CI 0.73–0.94, P = 0.004).
Conclusions: In a young at-risk South-Asian population, a pragmatic LSM programme significantly reduces the
incidence of predictors of cardio-metabolic disease. Our results highlight the importance of early intervention in
young at-risk subjects.
Trial registration: World Health Organization international clinical trial registry platform (SLCTR/2008/003).
Registration Date: March 28, 2008. Retrospectively registered.
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Background
The number of people with type 2 diabetes mellitus
(T2DM) is expected to reach 592 million by the year
2035, with 80% of all persons with diabetes living in low-
to middle-income countries [1, 2]. In parallel, the number
of adults with impaired glucose tolerance (IGT) will rise
from 316 million in 2013 to an estimated 471 million by
2035 [1]. Asia is the major site of the epidemic of T2DM,
accounting for 60% of the people with diabetes worldwide
[1]. South Asians are predisposed to early onset of T2DM,
with almost a third of future T2DM cases predicted to
occur in those aged below 45 years [2].
Sri Lanka is a middle-income Asian country with a
population of 20.3 million. Approximately 40% and 25%
of Sri Lankans are aged below 40 and 18 years, respect-
ively [3]. The prevalence of T2DM in urban Sri Lankans
is of 16.4% [4]. Lifestyle modification (LSM) has been
demonstrated to prevent the onset of T2DM in older
participants (aged > 40 years) with IGT [5–8]. Neverthe-
less, the effect of LSM on the onset of cardio-metabolic
disease in younger healthy participants has not been
studied to date.
Methods
Setting and participants
Prevention of cardio-metabolic disease with lifestyle modi-
fication in Sri Lanka (DIABRISK-SL) was a randomised
controlled clinical trial comparing a trimonthly pragmatic
LSM (P-LSM) programme with a less-intensive 12
monthly LSM (C-LSM) programme on a primary com-
posite endpoint of predictors of cardio-metabolic disease
in young urban healthy participants selected using a ‘high-
risk’ screening strategy.
We have previously reported in detail the design of
the study, trial protocol and baseline characteristics of
the cohort studied [9, 10]. Participants were recruited
following screening of a population of 23,298 representa-
tive of the general population of Colombo District, the
most populous urban district in Sri Lanka.
The screening strategy has been described in detail
previously [9]. The screening survey took place between
January 1, 2008, and June 30, 2009. More than 95% of sub-
jects and institutions approached agreed to participate.
Participants aged between 5 and 40 years were screened
to identify the prevalence of four risk factors, namely first
degree (parental) family history of T2DM, physical inactiv-
ity, raised body mass index (BMI), and raised waist cir-
cumference (WC). In participants aged between 5 and
17 years, raised WC was defined as ≥ 91st percentile for
sex and age, whereas in subjects aged 18–40 years it
was defined as ≥ 80 cm in females and as ≥ 90 cm in
males. Raised BMI was defined as a value greater than
internationally standardised age- and sex-specific per-
centile cut-offs in participants aged 5–17 years and as
BMI ≥ 23 kg/m2 in those aged between 18 and 40 years
[9]. Physical activity was measured using physical ac-
tivity questionnaire (IPAQ short version) and inactiv-
ity defined as less than 30 minutes continuous
exercise for less than 3 days a week [9]. In participants
younger than 15 years of age, where IPAQ is not fully
validated, the parents or guardians corroborated what
was reported.
In the screening phase results previously reported [10],
the prevalence of physical inactivity was nearly 52% in
those aged > 20 years. Participants with two or more risk
factors identified in the screening phase were invited to
take part in the clinical trial.
The inclusion criterion for the trial was participants
with two or more of the above risk factors. Exclusion
criteria were participants with no or one identifiable risk
factor, participants with diagnosed end-points (T2DM,
cardiovascular disease (CVD), hypertension and renal
disease), participants on any form of medication used
for the treatment of diabetes, hypertension, renal dis-
ease or dyslipidaemia, active communicable or non-
communicable diseases such as cancer, asthma or other
forms of chronic lung disease, depression, tuberculosis
and pregnancy.
All participants provided written informed consent
and the study was given ethical approval from the Sri
Lanka Medical Association Ethical Review Committee
(ERC 07-010). Permission from the Ministry of Educa-
tion was obtained for this study, which was conducted
under the Good Clinical Practice Guidelines and accord-
ing to the principles expressed in the Declaration of
Helsinki for clinical research.
Randomisation and interventions
Following screening of 23,298 participants, 5156 were
identified as being eligible for the trial. Of the 5156 partic-
ipants invited to take part in the trial, 4672 participants
attended the National Diabetes Centre where standardised
anthropometric and biochemical testing were performed
as previously described [9]. No lifestyle program/interven-
tions were delivered at this visit and participants were
randomised into two intervention trial arms P-LSM or C-
LSM using a computer generated randomisation sched-
ule/sequence (SPSS Inc., 233 South Wacker Drive, 11th
floor, Chicago, IL 60606-6412). There were no restrictions
such as blocking and block size. Allocation into the two
trial arms were implemented using sealed envelopes. En-
rolment and assignment of participants was performed by
a member of the research team. Participants and re-
searchers were not blinded to group assignment. The
CONSORT diagram showing the flow of participants is
shown in Additional file 1: Figure S1. The median (range)
follow-up was 3 (1-4) years.
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Intervention and goals
All participants received an identical lifestyle education
programme, with the only difference being the frequency
of the delivery of this advice (3 monthly or 12 monthly).
In the P-LSM group, advice was given every 3 months,
on a one-to-one basis, on the importance of a healthy
diet and lifestyle with the aim of reducing weight, en-
couraging regular exercise and managing psychological
stress, as described in detail previously [9]. Briefly, par-
ticipants with a raised BMI or WC were set a target
of > 5% weight loss over 12 months. In children, the
aim was to limit excessive weight gain. Participants
were advised to avoid a high intake of foods containing
simple sugars, refined carbohydrates and high saturated
fats (total fat < 20 g/day) and recommended to increase
their intake of fibre-rich natural foods such as whole-
grains, legumes, vegetables and fruits.
Participants with physical inactivity at baseline were
advised to increase physical activity to at least 30 minutes
of continuous exercise a day for more than 5 days a
week [11]. Children were advised on the need to play
sports they enjoyed (examples included running, netball,
cricket, badminton) for at least 1 hour every day [9, 11].
Sedentary activities such as playing computer games and
watching television were discouraged in all participants.
Peer educators were selected following local advertise-
ments for the positions, and were trained by specialist
nutritionists and diabetes specialists for 4 weeks prior to
starting work. The selection criteria were young persons
(aged 18 to 40 years) living in Colombo District with
secondary school education (with three advanced level
passes in studied subjects), and good communication
skills. A training manual was developed for the peer
educators and their training supervised by University of
Colombo staff, and two external experts on lifestyle
modification from South India. The standardised train-
ing manual was used by all the peer educators as a guide
to deliver the interventions.
Criteria for failing training included an inability to
demonstrate a sound understanding of the lifestyle
programme and intervention, and poor communication
skills after the training period. Approximately 20 peer
educators were trained during the study with a drop-out
rate of 25%. Monthly training refresher sessions were
performed throughout the study with peer-to-peer edu-
cation actively encouraged.
With regards to receipt of intervention, this component
of fidelity was evaluated by recording attendance at ses-
sions, adherence to goals set and impact of the interven-
tion on motivation by assessing behaviour change and
readiness to change as detailed below. Each session lasted
at least 30 minutes. In younger children (age < 16 years)
the LSM advice and guidance was also given to the child’s
parents. A readiness to change ruler and questionnaire
was utilised to assess behaviour change [12]. Participants
were asked about their readiness to change before asses-
sing the results. These parameters were used to facilitate
the participants’ understanding of the importance of be-
haviour change and to aid the delivery of the intervention.
The stages of behaviour change were defined as pre-
action (pre-contemplation, contemplation and prepar-
ation) and action (action and maintenance), using the
trans-theoretical model of behaviour change [12].
The presence or absence of stress and depression was
assessed at each visit using the Perceived Stress Score
Questionnaire and the Patient Health Questionnaire 9
[10]. Participants were provided counselling and advice
on pragmatic strategies to reduce stress. It was empha-
sised that improving lifestyle would have a positive impact
on perceived stress and anxiety levels over the duration of
the study.
All participants in the intensive group received
trimonthly individualised LSM advice to assess progress
(P-LSM). If needed, goals were reiterated and reinforced.
The control group (C-LSM) received lifestyle advice an-
nually, which was identical in format and structure to
that provided to participants in the P-LSM group. The
control group received annual LSM counselling as it
would have been unethical to withhold any intervention
in participants considered to be at future risk.
Outcomes and follow-up
The primary composite cardio-metabolic endpoint was
new onset T2DM, hypertension, IGT, impaired fasting
glycaemia (IFG), CVD and renal disease. New cases of
T2DM (fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L)
or an oral glucose tolerance test (OGTT) with the 2-h post-
load value ≥ 200 mg/dL (11.1 mmol/L)), IGT (2-h post
load plasma glucose ≥ 140 (7.8 mmol/L) and < 200 mg/
dL (11.1 mmol/L)), IFG (fasting plasma glucose ≥ 100
(5.6 mmol/L) and < 126 mg/dL (7.0 mmol/L)) were diag-
nosed according to the American Diabetes Association
criteria [11, 13].
Endpoints were diagnosed at the time of follow-up
visits or if made by the participant’s family physician and
confirmed on repeat testing. Participants with IFG or
IGT diagnosed at baseline evaluation were eligible to
participate in the trial. In these subjects, development of
T2DM was the metabolic endpoint. Participants with
endpoint diagnoses, including diagnosis of diabetes,
underwent medical and clinical review. All participants
with a new diagnosis of diabetes had a clinical history
and features of T2DM. No participant with a diagnosis
of new onset diabetes had clinical or biochemical fea-
tures indicative of type 1 diabetes. Furthermore, none of
the participants diagnosed required insulin treatment or
displayed any features of insulin deficiency.
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In adults, new cases of hypertension were defined as
brachial blood pressure ≥ 140/90 mmHg; in subjects
aged below 18 years, hypertension was defined following
Joint National Committee 7 guidelines (blood pressure
that is, on repeated measurement, at the 95th percentile
or greater adjusted for age, height and sex) [12]. Renal
disease was defined as new onset microalbuminuria
(urine albumin/creatinine ratio of ≥ 22 mg/g in men
and ≥ 31 mg/g in women confirmed on one repeat test)
or new onset renal impairment defined as estimated
GFR < 60 mL/min [9]. Initiation of statin therapy was in-
cluded in the primary composite endpoint in view of re-
cent substantive data that this class of drugs can
influence glucose levels [14]. Because of the young age
range of our study population the composite outcome
was composed of predictors/risk factors for clinical
events with the addition of CVD events and all cause
death. Participants were asked about events and only
positive events were followed by review of hospital re-
cords. CVD event information was obtained from local
hospital records, and when participants gave a positive
response they were asked about events.
The choice of risk factors in the primary outcome is
clearly relevant to the younger age groups as occurrence
of these risk factors has been shown to occur in child-
hood and track with time [15, 16].
Statistical analysis
No information was available in a population compar-
able to the one reported on in this proof of concept
work and hence the power calculation was largely hy-
pothesis driven and based on risk reductions for new on-
set T2DM in older IGT subjects observed with more
intensive LSM from South Asia [7]. We assumed a 15%
incidence of the primary end-point in the C-LSM group
and estimated that approximately 2300 participants in
each group will enable the detection of at least 25% rela-
tive risk reduction in the primary endpoint with P-LSM,
at the 90% power level with a type-1 error of 0.05 (two-
sided) [9]. Descriptive statistics were used for the ana-
lysis of demographic and clinical features of the cohort.
Comparison of proportions was performed by χ2 ana-
lysis. Analyses of the incidence of dysglycaemia and the
impact of the intervention in participants above and
below 18 years of age were not pre-specified and per-
formed post hoc. Regression analyses were used to esti-
mate mean differences between the groups at the end of
the study, which were adjusted for baseline value. For
the biomarker endpoints, the last observation was car-
ried forward for those participants with missing end-
point values who did not complete the full duration of
the trial. There was no interim analysis performed.
The final analysis was in the intent-to-treat population,
who were randomised and had at least one post-
randomisation visit/evaluation where intervention was
delivered. We also report analyses for all participants
who attended randomisation irrespective of whether they
attended their first post-randomisation visit.
We had originally proposed to perform survival ana-
lysis to estimate the cumulative incidence end-points
and test the difference between the groups by means of
the two-sided log-rank test. However, we updated the
analyses plan to Poisson multivariate regression analyses
(analyses were performed by the statistician on blinded
data set) rather than survival analyses due to the follow-
ing reasons. The Poisson approach is suitable when ana-
lysing time to event data when times between successive
events are independent and exponentially distributed
and the distribution of follow-up times similar for both
groups (as was the case in our data set). In this scenario,
a survival analysis would not be the most robust form of
analyses because end points could not be observed con-
tinuously. Moreover, the Poisson method enables an effi-
cient method to deal with cumulative exposure and
other time-dependent covariates and allows for risk to
depend on multiple timelines [17, 18]. Poisson regression
analyses were performed, with person-time as exposure, to
estimate the incident rate ratio (IRR) with P-LSM as com-
pared to C-LSM. Analyses were performed using SPSS
software version Version 20.0. Armonk, NY, USA. Data
are given as mean with 95% confidence intervals (CI) un-
less otherwise stated. A P value of less 0.05 was considered
significant.
Results
The clinical and biochemical features of the screened
population have been previously reported [10]. In brief,
of the 23,298 participants screened, 5156 were eligible
and 4672 participants attended the National Diabetes
Centre to have baseline assessments and received the al-
located intervention.
Of the 4672 participants, 3539 (76%) were eligible
for analysis. In total, 1133 participants (approximately
24% of subjects, similarly distributed between trial
arms) were excluded from the analysis as they failed
to attend any LSM advice visits after the baseline ran-
domisation visit. These participants had a similar
mean age and prevalence of baseline risk factors as
compared to participants who attended visits post
randomisation, but had modestly higher blood pres-
sure levels and lower glucose levels (Additional file 2:
Table S1).
The baseline clinical and biochemical characteristics of
participants in the two trial arms were similar, with no
statistically significant differences between the two arms
(Table 1). The prevalence of raised BMI, raised WC, and
parental family history of T2DM in the P-LSM and in
the C-LSM trial arms were similar at baseline. The
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prevalence of physical inactivity strictly by definition was
100% in both arms (as all participants eligible to enter
clinical trial reported less than 30 minutes continuous
exercise for less than 3 days a week). The number of
participants who were tobacco smokers and consumed
alcohol were comparable in the two trial arms (Table 1).
At baseline, there was a similar prevalence of IFG
and IGT. Stage of behaviour change for diet, exercise
and stress were similar at baseline in both groups and
more than 80% of participants were in the pre-action
phase.
Table 2 details the number of participants in the P-LSM
and C-LSM groups who developed the respective individ-
ual components of the primary composite endpoint in the
whole cohort with the respective IRR comparing the two
groups. After a median follow-up of 3 years, the cumula-
tive incidence of the primary composite cardio-metabolic
endpoint was n = 479 in P-LSM (74 per 1000 person
years) versus 561 in C-LSM (96 per 1000 person years),
with an IRR of 0.89 (95% CI 0.83–0.96, P = 0.002)
(Table 2).
New onset hypertension was significantly reduced with
P-LSM (IRR 0.79, 95% CI 0.68–0.9, P = 0.01). In com-
parison with the C-LSM, fewer patients developed new
onset T2DM, IFG and IGT with P-LSM; however, the
risk reductions observed were not significant.
New onset dysglycaemia (defined post hoc as a compos-
ite of T2DM, IFG and IGT) was the major contributor to
the composite and was significantly reduced by P-LSM
(IRR 0.9, 95% CI 0.83–0.97, P = 0.01).
Table 3 shows the post hoc analyses results and break-
down of the individual components of the primary com-
posite endpoint in those above and below 18 years of
age with the respective IRR comparing the two groups.
The impact of P-LSM on the incidence of the composite
endpoint was observed in participants aged below 18;
P-LSM n = 140 (48 per 1000 person years) versus C-LSM
n = 174 (55.4 per 1000 person years), with an IRR of 0.83
(95% CI 0.73–0.94, P = 0.004). A significant reduction in
new onset IGT (P-LSM n = 46 vs. C-LSM n = 63, IRR 0.74,
95% CI 0.6–0.9, P = 0.009), T2DM (P-LSM n = 4 vs. C-
LSM n = 9, IRR 0.48, 95% CI 0.24–0.94, P = 0.03) and
Table 1 Baseline characteristics of 3539 healthy participants who received pragmatic lifestyle modification or control lifestyle
modification
Characteristics Pragmatic lifestyle modification Control lifestyle modification
Number 1726 1813
Age, mean (range) years 22.5 (6–40) 22.4 (7–40)
Sex, %
Males 837 (48.5%) 877 (48.4%)
Female 889 (51.5% 936 (51.6%)
Prevalence of raised BMI, % 69.1 69.8
Prevalence of raised WC, % 63.0 64.4
Prevalence of a FH of T2DM, % 52.0 52.1
Prevalence of physical inactivity, % 100 100
Impaired fasting glycaemia, % 7.8 8.2
Impaired glucose tolerance, % 7.9 8.3
Smokers 5.7% 6.4%
Alcohol use 16% 17%
Waist circumference, cm 84.3 (83.7–84.8) 84.1 (83.5–84.5)
Body mass index, kg/m2 24.0 (23.8–24.2) 24.0 (23.7–24.1)
Systolic blood pressure, mmHg 114.1 (113.8–115.1) 114.0 (113.8–115.0)
Diastolic blood pressure, mmHg 71.0 (70.5–71.5) 71.1 (70.9–71.9)
Fasting plasma glucose, mmol/L 4.95 (4.9–5.0) 4.95 (4.9–5.0)
2-hour post-oral glucose tolerance test plasma glucose, mmol/L 5.84 (5.8–5.9) 5.91 (5.8–6.0)
Total cholesterol, mmol/L 4.95 (4.90–4.96) 4.96 (4.92–5.0)
Low density lipoprotein, mmol/L 3.19 (3.15–3.22) 3.22 (3.19–3.26)
High density lipoprotein, mmol/L 1.14 (1.13–1.15) 1.14 (1.13–1.16)
Serum triglycerides, mmol/L 1.25 (1.22–1.28) 1.27 (1.24–1.31)
Data are mean and 95% confidence intervals unless otherwise stated
There were no statistically significant differences between the two trial arms
BMI body mass index, WC waist circumference, FH family history, T2DM type 2 diabetes mellitus
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hypertension (P-LSM n = 33 vs. C-LSM n = 57, IRR 0.6,
95% CI 0.47–0.76, P = 0.001) was also observed with P-
LSM in participants aged below 18 years of age (Table 3).
In those participants above 18 years of age, a sig-
nificant reduction in new onset IFG was observed
with P-LSM (n = 88) versus C-LSM (n = 115), with an
IRR of 0.78 (95% CI 0.67–0.91, P = 0.02), and a trend
toward less new onset dysglycaemia P-LSM (n = 253)
versus C-LSM (n = 303), with an IRR of 0.9 (95% CI,
0.82 to 1.00, P = 0.051).
Table 2 Effect of pragmatic lifestyle modification as compared to control lifestyle modification on the incidence of the primary
cardio-metabolic composite endpoint and its individual components in 3539 healthy participants
Component of primary composite
end-point
Pragmatic lifestyle modification
n = 1726
Control lifestyle modification
n = 1813
Incident rate ratio (95% confidence
intervals)
P value
Composite 479 561 0.89 (0.83–0.96) 0.002
New onset T2DM 58 72 0.8 (0.65–1.02) 0.08
New onset IGT 143 168 0.89 (0.79–1.01) 0.08
New onset IFG 146 166 0.93 (0.82–1.06) 0.27
New onset dysglycaemiaa 347 406 0.9 (0.83–0.97) 0.013
Hypertension 115 152 0.79 (0.68–0.9) 0.01
Statin therapy 41 46 0.92 (0.72–1.18) 0.5
Renal disease events 2 8 0.26 (0.1–0.63) 0.003
Cardiovascular events 1 0 N/A
Deaths 2 0 N/A
aComposite of T2DM, IFG and IGT. T2DM type 2 diabetes mellitus, IGT impaired glucose tolerance, IFG impaired fasting glycaemia, N/A not applicable
Table 3 Effect of pragmatic lifestyle modification as compared to control lifestyle modification on the incidence of the primary
cardio-metabolic composite endpoint and its individual components in 1814 healthy participants aged above 18 and 1725 below
18 years of age
Component of primary composite
endpoint
Pragmatic lifestyle
modification
Control lifestyle
modification
Incident rate ratio
(95% confidence Intervals)
P value
Participants aged≥ 18 years n = 876 n = 938
Composite 339 387 0.93 (0.86–1.03) 0.11
New onset T2DM 54 63 0.9 (0.73–1.11) 0.35
New onset IGT 97 105 1.01 (0.87–1.17) 0.89
New onset IFG 88 115 0.78 (0.67–0.91) 0.02
New onset dysglycaemiaa 239 283 0.9 (0.82–1.00) 0.051
Hypertension 82 95 0.91 (0.77–1.089) 0.31
Statin therapy 38 45 0.89 (0.69–1.15) 0.39
Renal disease events 0 4 N/A
Cardiovascular events 1 0 N/A
Deaths 1 0 N/A
Participants aged < 18 years n = 850 n = 875
Composite 140 174 0.83 (0.73–0.94) 0.004
New onset T2DM 4 9 0.48 (0.24–0.94) 0.032
New onset IGT 46 63 0.74 (0.60–0.90) 0.009
New onset IFG 58 51 1.13 (0.93–1.4) 0.13
New onset dysglycaemiaa 113 133 0.91 (0.79–1.03) 0.24
Hypertension 33 57 0.60 (0.47–0.76) 0.001
Statin therapy 3 1 2.89 (0.77–10.7 0.11
Renal disease events 2 4 0.5 (0.19–1.33) 0.16
Cardiovascular events 0 0 N/A
Deaths 1 0 N/A
aComposite of T2DM, IFG and IGT. T2DM type 2 diabetes mellitus, IGT impaired glucose tolerance, IFG impaired fasting glycaemia, N/A not applicable
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In post-hoc analyses of all participants who were ran-
domised (including those who failed to attend for any
LSM advice after the baseline randomisation visit), the
results for the primary endpoint demonstrated a similar
significant risk reduction with P-LSM (IRR 0.86, 95% CI
0.80–0.93, P = 0.001) and risk reductions comparable to
what we detail above were also observed for the individ-
ual components of the primary endpoint.
End of study values for selected clinical and biochem-
ical variables, adjusted for baseline value, age and sex for
participants above and below 18 years of age in the P-
LSM and C-LSM groups are shown in Additional file 2:
Table S2. At the end of the trial, there was a small but
statistically significant lower fasting plasma glucose and
2-h post-OGTT plasma glucose level in the P-LSM as
compared to the C-LSM group in participants aged
above 18 years of age only (P < 0.05 for both). Blood
pressure, anthropometric and lipid parameters were not
significantly different between the two groups at the end
of the study.
The percentage of participants adhering to LSM advice
and achieving weight loss and improving related behav-
iour change from baseline was similar in both groups
(Additional file 2: Table S3). Physical activity (defined
as > 600 MET/min-week) increased from a baseline of
39% in both groups to 47.2% in P-LSM and 42% C-LSM,
with a significant difference between groups in partici-
pants both above and below 18 years of age. There was
also a significant effect of P-LSM as compared to C-LSM
to increase behaviour change with regards to increasing
physical activity, an effect that was observed in partici-
pants above and below 18 years of age (Additional file 2:
Table S3).
Adverse events
There were two deaths during the study, both in P-LSM
(the causes of death were road traffic accident and haem-
atological malignancy), and one CVD event in P-LSM.
Discussion
The results from our translational proof of concept trial
demonstrates that a peer educator-delivered P-LSM inter-
vention of trimonthly advice results in a significantly lower
incidence rate of predictors of cardio-metabolic endpoints
in young South Asians with risk factors for T2DM and
CVD. The majority of endpoint events were metabolic
glucose abnormalities, with a significant reduction in new
onset dysglycaemia (new onset T2DM, IFG and IGT) with
P-LSM. We also observed significant reduction in new on-
set hypertension with P-LSM. Interestingly, the benefi-
cial effects of P-LSM on the primary composite cardio-
metabolic endpoint, new onset T2DM, new IGT and
hypertension were observed in participants below 18 years
of age.
The cumulative incidence of T2DM we observed was
much lower than that observed in previous studies of
LSM such as the Diabetes Prevention Program (DPP) [5]
in the United States, Finnish Diabetes Prevention study
(DPS) [6], the Indian Diabetes Prevention Programme
(IDPP) [7], and the Da Qing Diabetes Prevention study
[8]. These seminal studies focussed on higher risk, older
(mean age 50 years) participants with baseline IGT [5–8].
In contrast, our study was focused on younger (mean age
22.5 years), healthier participants, of whom 92% had nor-
mal glucose tolerance at baseline.
The control group in our study received goal-orientated
LSM advice with the same targets as the P-LSM group, al-
beit at a lower intensity. This would have contributed to
the smaller relative risk reductions and incident rates of
T2DM we observed as compared to previous studies, and
could result in an underestimation of the true risk reduc-
tion with the P-LSM intervention [5].
It is reasonable to suggest that reduction in risk with P-
LSM of dysglycaemia and hypertension, two conditions
causally related to CVD, may translate over time into
fewer cardiovascular events [19, 20]. However, this re-
mains to be demonstrated in younger populations such as
ours, but recent data from the longer term follow-up of
the Da Qing study cohort supports this premise [21].
The main strengths of our study are the young healthy
population, a sample not previously evaluated in the
context of diabetes prevention, the large number of par-
ticipants and the relatively long follow-up period. Our
study is the first demonstration in participants below the
age of 18 years that lifestyle modification delivered by
peer educators reduces the development of predictors of
cardio-metabolic disease. We also used a novel delivery
of LSM advice on a one-to-one basis by peer educators,
which was very effective.
The cost of peer educators to deliver the intervention
would be significantly lower than recruiting registered die-
titians or behaviour-change counsellors as has been used
in other trials [5]. We contend that such a pragmatic,
cost-effective approach is therefore translatable to other
developing and middle-income countries. We can also
speculate that this younger population may be more
‘responsive’ and amenable to change compared to older
participants, particularly when delivered by peers. Import-
antly, any reduction in the future risk of dysglycaemia and
hypertension would be of significant health impact, espe-
cially in view of the growing worldwide burden of cardio-
metabolic disease in younger populations [2, 10].
There are limitations to our study. The specific mecha-
nisms that explain the reduction in the primary cardio-
metabolic endpoint with the P-LSM intervention are un-
clear. In our trial, P-LSM had no effect on weight loss.
The Da Qing study demonstrated no significant weight
loss and that weight change was not related to reduction
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in new onset T2DM [8]. Similar results were observed in
the IDDP [7]. These results from Asian participants are at
variance with results from predominantly Caucasian par-
ticipants studied in the North American DPP and Finnish
DPS, in which the impact of lifestyle modification on pre-
venting T2DM was mostly driven by weight loss, though
physical activity also increased [5, 6, 22].
Our P-LSM intervention resulted in increased physical
activity and improved behaviour change to increase phys-
ical activity and this was true for participants both above
and below 18 years of age. Exercise, even in the absence of
weight loss, is known to improve insulin sensitivity, which
is a key determinant of the 2-hour glucose concentration
following an OGTT [23, 24]. However, our study was not
designed to examine the mechanism of effect or test the
relative contributions of weight change and physical activ-
ity on cardio-metabolic endpoints. Our results indicate
that, at least in young healthy South Asian participants,
weight loss per se is not essential for reducing the risk of
cardio-metabolic disease and we can speculate that in-
creased physical activity may be an important factor [2, 7,
22]. Our findings reinforce the need for future research in
this area.
There was little evidence of improvement in metabolic
variables with P-LSM. These results reflect the relatively
healthy baseline population we studied as compared to
other T2DM prevention trials [25–27].
Our findings in a young urban population may not be
generalisable to other groups. The annual structured
LSM advice received by the C-LSM control group may
have resulted in an underestimation of the risk reduction
that would be seen with P-LSM under ordinary circum-
stances. An alternative view could be that modest risk
reduction observed may be realistic in view of public in-
formation on healthy living currently available in urban
Sri Lanka.
Attrition could have caused bias if those with symp-
toms were more likely to return for follow-up. However,
participants might have also defaulted because they were
too ill to attend. We have no evidence for or against ei-
ther of these situations. Nearly 24% of randomised par-
ticipants were not eligible for analyses as they did not
attend any visits to receive lifestyle advice and we had
no follow-up data available on them. These participants
had similar baseline features as compared to those who
were eligible for analyses but the lack of follow-up infor-
mation is a significant limitation of our work. The analyses
of participants below 18 years was not pre-specified; how-
ever, our results establish the platform and rationale for
further studies in this population.
We chose trimonthly visits in the P-LSM trial arm as
this was the most feasible and pragmatic intervention
schedule/programme that could be delivered in the con-
text of the study population, with the available resources.
Previous studies, such as the DPP, DPS and IDPP were
proven to be cost effective. Our relatively conservative
P-LSM programme with four visits a year undertaken by
young peer educators is likely to be at least as cost-
effective, but detailed cost-benefit and economic ana-
lyses are required and planned.
Conclusions
We take the view that, in South Asian subjects, who are
known to be at enhanced and premature risk of T2DM
and CVD, early interventions that can delay or prevent
onset of cardio-metabolic endpoints are of clinical im-
portance. Longer term follow-up of the DPP and Da
Qing study cohorts showed a lasting effect of the ori-
ginal life change intervention with a significant reduc-
tion in new onset T2DM up to 10–14 years later [28,
29] and cardiovascular and all-cause mortality [21]. This
suggests a significant legacy effect of the intervention
and emphasises the importance of early intervention es-
pecially in a younger at-risk group. Recent publications
highlight the urgent need and beneficial impact of dia-
betes prevention and implementation into general prac-
tice and promote the concept that even small changes in
lifestyle can result in big changes in health [30, 31].
In summary, this is the first study to prove that in an at-
risk urban South Asian population, across a wide range of
young ages, a pragmatic lifestyle modification programme
can significantly reduce the development of risk factors
that are causally related to future development of T2DM
and CVD in later life. Our study highlights the importance
of early intervention and establishes the proof of concept
and rationale for further pragmatic lifestyle modification
intervention studies in young South Asian participants at
risk of cardio-metabolic disease.
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